Is there a role for fluorine-18 fluorodeoxyglucose positron emission tomography imaging in medullary thyroid cancer?

Endocrine

Volumn 42, Issue 3, 2012, Pages 461-463

  Kauhanen, Saila ^a   Schalin Jäntti, Camilla ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN GA 68; UNCLASSIFIED DRUG; VANDETANIB; DIAGNOSTIC AGENT;

CANCER GROWTH; CHEMOEMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; METHODOLOGY; NOTE; SCINTISCANNING; THYROID TUMOR;

FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 84878305161     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9740-x     Document Type: Editorial

References (15)

1. E. Kebebew, O.H. Clark, Medullary thyroid cancer. Curr. Treat. Options Oncol. 1, 359-367 (2010)
2. G. Pellegriti, S. Leboulleux, E. Baudin, N. Bellon, C. Scollo, J.P. Travagli, M. Schlumberger, Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br. J. Cancer 88, 1537-1542 (2003)
3. M. Sclumberger, L. Bastholt, H. Dralle, B. Jarzab, F. Pacini, J.W.A. Smit, The European Thyroid Association guidelines 2012 European Thyroid Association guidelines for metastatic medullary thyroid cancer. Eur. Thyroid J 1, 5-14 (2012)
4. G. Treglia, M.F. Villani, A. Giordano, V. Rufini, Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine (2012). doi: 10.1007/s12020-012-9671-6
5. E. Skoura, I.E. Datseris, P. Rondogianni, S. Tsagarakis, M. Tzanela, M. Skilakaki, D. Exarhos, M. Alevizaki, Correlation between calcitonin levels and [(18)F]FDG-PET/CT in the detection of recurrence in patients with sporadic and hereditary medullary thyroid cancer. ISRN Endocrinol (2012). doi: 10.5402/2012/375231
6. S. Kauhanen, C. Schalin-Jantti, M. Seppanen, S. Kajander, S. Virtanen, J. Schildt, I. Lisinen, A. Ahonen, I. Heiskanen, M. Vaisanen, J. Arola, P. Korsoff, T. Ebeling, T. Sane, H. Minn, M.J. Valimaki, P. Nuutila, Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J. Nucl. Med. 52, 1855-1863 (2011)
7. S.C. Ong, H. Schoder, S.G. Patel, I.M. Tabangay-Lim, I. Doddamane, M. Gonen, A.R. Shaha, R.M. Tuttle, J.P. Shah, S.M. Larson, Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J. Nucl. Med. 48, 501-507 (2007)
8. K.P. Koopmans, J.W. de Groot, J.T. Plukker, E.G. de Vries, I.P. Kema, W.J. Sluiter, P.L. Jager, T.P. Links, 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J. Nucl. Med. 49, 524-531 (2008)
9. M. Beheshti, S. Pocher, R. Vali, P. Waldenberger, G. Broinger, M. Nader, S. Kohlfurst, C. Pirich, H. Dralle, W. Langsteger, The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur. Radiol. 19, 1425-1434 (2009)
10. G. Treglia, P. Castaldi, M.F. Villani, G. Perotti, C. de Waure, A. Filice, V. Ambrosini, N. Cremonini, M. Santimaria, A. Versari, S. Fanti, A. Giordano, V. Rufini, Comparison of 18F-DOPA, 18F-FDG and 68 Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 39, 569-580 (2012)
11. A.L. Giraudet, D. Vanel, S. Leboulleux, A. Auperin, C. Dromain, L. Chami, N.N. Tovo, J. Lumbroso, N. Lassau, G. Bonniaud, D. Hartl, J.P. Travagli, E. Baudin, M. Schlumberger, Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185-4190 (2007)
12. G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine (2012). doi: 10.1007/s12020-012-9631-1
13. S. Koukouraki, L.G. Strauss, V. Georgoulias, J. Schuhmacher, U. Haberkorn, N. Karkavitsas, A. Dimitrakopoulou-Strauss, Evaluation of the pharmacokinetics of 68 Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33, 460-466 (2006)
14. B.G. Conry, N.D. Papathanasiou, V. Prakash, I. Kayani, M. Caplin, S. Mahmood, J.B. Bomanji, Comparison of (68)Ga-DOTATATE and (18)F- fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 37, 49-57 (2010)
15. J.C. Reubi, J.C. Schaer, B. Waser, G. Mengod, Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 54, 3455-3459 (1994)